| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | J E Morgan | |
| C A Collins | |||
| P2860 | cites work | X chromosome-linked muscular dystrophy (mdx) in the mouse | Q28589078 |
| Normal myoblast injections provide genetic treatment for murine dystrophy | Q68420325 | ||
| Muscle precursor cells invade and repopulate freeze-killed muscles | Q68781971 | ||
| Mdx muscle grafts retain the mdx phenotype in normal hosts | Q69617523 | ||
| Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse | Q70039598 | ||
| Muscle development in mdx mutant mice | Q70804155 | ||
| Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy | Q71952881 | ||
| Expression of utrophin (dystrophin-related protein) during regeneration and maturation of skeletal muscle in canine X-linked muscular dystrophy | Q72377687 | ||
| [Muscular dystrophy in a cat] | Q72628350 | ||
| Canine X-linked muscular dystrophy in Japan (CXMDJ) | Q73525127 | ||
| Myoblast transplantation in whole muscle of nonhuman primates | Q73614007 | ||
| In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide | Q73844338 | ||
| Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice | Q73851362 | ||
| T-cell-dependent fibrosis in the mdx dystrophic mouse | Q73952718 | ||
| Development of muscle pathology in canine X-linked muscular dystrophy. II. Quantitative characterization of histopathological progression during postnatal skeletal muscle development | Q74310479 | ||
| Dystrophin in adult zebrafish muscle | Q74393273 | ||
| Changes of skeletal muscle in young dystrophin-deficient cats: a morphological and morphometric study | Q74408052 | ||
| The worm in us - Caenorhabditis elegans as a model of human disease | Q77800192 | ||
| Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury | Q77974446 | ||
| Cardiomyopathy in dystrophin-deficient hypertrophic feline muscular dystrophy | Q78130933 | ||
| Dystrophin: the protein product of the Duchenne muscular dystrophy locus | Q29618077 | ||
| Molecular analysis of a spontaneous dystrophin 'knockout' dog. | Q30735735 | ||
| The dystrophin associated protein complex in zebrafish | Q31134324 | ||
| Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle | Q33787827 | ||
| Progress in myoblast transplantation: a potential treatment of dystrophies | Q33840950 | ||
| Muscular dystrophy: the worm turns to genetic disease | Q34085566 | ||
| Harnessing the potential of dystrophin-related proteins for ameliorating Duchenne's muscular dystrophy | Q34285869 | ||
| Long-term persistence and migration of myogenic cells injected into pre-irradiated muscles of mdx mice | Q34306103 | ||
| Murine muscular dystrophy caused by a mutation in the laminin alpha 2 (Lama2) gene | Q34319775 | ||
| Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD? | Q34807072 | ||
| Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin | Q34807084 | ||
| Oligonucleotide-mediated gene therapy for muscular dystrophies | Q34807121 | ||
| Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. | Q35056189 | ||
| Non-viral gene delivery in skeletal muscle: a protein factory | Q35061706 | ||
| Zebrafish: from disease modeling to drug discovery. | Q35096379 | ||
| Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: rationale. | Q40635064 | ||
| Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse | Q41902045 | ||
| Deficiency of merosin in dystrophic dy mice and genetic linkage of laminin M chain gene to dy locus | Q42501151 | ||
| Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts | Q43465378 | ||
| Comparative evolution of muscular dystrophy in diaphragm, gastrocnemius and masseter muscles from old male mdx mice | Q43717688 | ||
| Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies | Q43955218 | ||
| Efficacy of myoblast transplantation in nonhuman primates following simple intramuscular cell injections: toward defining strategies applicable to humans | Q43992517 | ||
| Remission of clinical signs in early duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy | Q44167443 | ||
| Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. | Q44241921 | ||
| Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. | Q44255035 | ||
| Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. | Q44409495 | ||
| Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. | Q44434265 | ||
| Tarsal joint contracture in dogs with golden retriever muscular dystrophy | Q44864009 | ||
| High-efficiency plasmid gene transfer into dystrophic muscle | Q45859128 | ||
| Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene | Q45865580 | ||
| Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle. | Q45887463 | ||
| Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. | Q45956233 | ||
| In vitro interactions of Caenorhabditis elegans dystrophin with dystrobrevin and syntrophin. | Q47068721 | ||
| Mutations in the Caenorhabditis elegans dystrophin-like gene dys-1 lead to hyperactivity and suggest a link with cholinergic transmission | Q47068751 | ||
| Dystrobrevin- and dystrophin-like mutants display similar phenotypes in the nematode Caenorhabditis elegans. | Q47068987 | ||
| Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping | Q47947457 | ||
| The dystrophin / utrophin homologues in Drosophila and in sea urchin | Q48378746 | ||
| Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. | Q50892927 | ||
| High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. | Q53956299 | ||
| A New Immunodeficient Mouse Model for Human Myoblast Transplantation | Q57268530 | ||
| The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs | Q59051983 | ||
| Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy | Q61828055 | ||
| The mdx mouse skeletal muscle myopathy: II. Contractile properties | Q68025103 | ||
| Ultrastructure of the skeletal muscle in the X chromosome-linked dystrophic (mdx) mouse. Comparison with Duchenne muscular dystrophy | Q68055667 | ||
| P433 | issue | 4 | |
| P921 | main subject | muscular dystrophy | Q1137767 |
| P304 | page(s) | 165-172 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | International Journal of Experimental Pathology | Q15750807 |
| P1476 | title | Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies | |
| P478 | volume | 84 |
| Q35761079 | A COLQ Missense Mutation in Sphynx and Devon Rex Cats with Congenital Myasthenic Syndrome |
| Q45303122 | A Nematode Nobel Prize: Caenorhabditis elegans |
| Q33810272 | A mathematical model of skeletal muscle disease and immune response in the mdx mouse. |
| Q28576151 | Age-related dystrophin-glycoprotein complex structure and function in the rat extensor digitorum longus and soleus muscle |
| Q30497616 | An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed |
| Q37059675 | Animal models for genetic neuromuscular diseases |
| Q34708380 | Bmi1 enhances skeletal muscle regeneration through MT1-mediated oxidative stress protection in a mouse model of dystrophinopathy |
| Q34665595 | Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs |
| Q36392294 | Challenges for gene therapy for muscular dystrophy |
| Q50422172 | Clinical and genetic characterisation of dystrophin-deficient muscular dystrophy in a family of Miniature Poodle dogs. |
| Q92996733 | Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients |
| Q33290644 | Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice |
| Q81820857 | Degeneration of dystrophic or injured skeletal muscles induces high expression of Galectin-1 |
| Q30856794 | Development and use of DNA archives at veterinary teaching hospitals to investigate the genetic basis of disease in dogs |
| Q36501691 | Dilated cardiomyopathy: a tale of cytoskeletal proteins and beyond |
| Q24791491 | Diseased muscles that lack dystrophin or laminin-alpha2 have altered compositions and proliferation of mononuclear cell populations |
| Q38480698 | Drug Discovery of Therapies for Duchenne Muscular Dystrophy |
| Q47704855 | Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification. |
| Q35911460 | Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment |
| Q35052506 | Duchenne muscular dystrophy gene therapy: Lost in translation? |
| Q83044679 | Eccentric stimulation reveals an involvement of FGF6 in muscle resistance to mechanical stress |
| Q90734610 | Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice |
| Q33840407 | Excitation-contraction coupling alterations in mdx and utrophin/dystrophin double knockout mice: a comparative study |
| Q37271171 | Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover |
| Q64898517 | Extracellular microRNAs exhibit sequence-dependent stability and cellular release kinetics. |
| Q37396408 | Gene therapy in large animal models of muscular dystrophy |
| Q59128911 | Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy |
| Q36444141 | Genetic elevation of sphingosine 1-phosphate suppresses dystrophic muscle phenotypes in Drosophila |
| Q92922123 | Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies |
| Q37899626 | Getting priorities straight: risk assessment and decision-making in the improvement of inherited disorders in pedigree dogs |
| Q36832437 | Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. |
| Q30571229 | In vitro Differentiation of Functional Human Skeletal Myotubes in a Defined System |
| Q41151043 | Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy |
| Q34691050 | Induction of revertant fibres in the mdx mouse using antisense oligonucleotides |
| Q41096343 | Influence of Botulinumtoxin A on the Expression of Adult MyHC Isoforms in the Masticatory Muscles in Dystrophin-Deficient Mice (Mdx-Mice). |
| Q36707428 | Inhibition of CaMKII phosphorylation of RyR2 prevents inducible ventricular arrhythmias in mice with Duchenne muscular dystrophy. |
| Q27438151 | Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression |
| Q46202556 | Intestine of dystrophic mice presents enhanced contractile resistance to stretching despite morphological impairment |
| Q36178999 | Invertebrate muscles: muscle specific genes and proteins |
| Q37184680 | Kinematics of gait in golden retriever muscular dystrophy. |
| Q33649312 | Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy |
| Q47074096 | Loss of selenoprotein N function causes disruption of muscle architecture in the zebrafish embryo. |
| Q26991681 | Model organisms in the fight against muscular dystrophy: lessons from drosophila and Zebrafish |
| Q36748510 | Modeling inflammatory bowel disease: the zebrafish as a way forward. |
| Q53180281 | Molecular hydrogen alleviates motor deficits and muscle degeneration in mdx mice. |
| Q35142741 | Motor physical therapy affects muscle collagen type I and decreases gait speed in dystrophin-deficient dogs. |
| Q40422606 | Muscle costameric protein, Chisel/Smpx, associates with focal adhesion complexes and modulates cell spreading in vitro via a Rac1/p38 pathway. |
| Q30578452 | Myogenic potential of canine craniofacial satellite cells. |
| Q40490992 | Non-Targeted Metabolomics Analysis of Golden Retriever Muscular Dystrophy-Affected Muscles Reveals Alterations in Arginine and Proline Metabolism, and Elevations in Glutamic and Oleic Acid In Vivo |
| Q28072269 | Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture |
| Q28547478 | Profiles of Steroid Hormones in Canine X-Linked Muscular Dystrophy via Stable Isotope Dilution LC-MS/MS |
| Q38391853 | Quantitative proteome profiling of dystrophic dog skeletal muscle reveals a stabilized muscular architecture and protection against oxidative stress after systemic delivery of MuStem cells. |
| Q59700731 | Retracted: ‘The effects of Duchenne muscular dystrophy on the performance of the stomatognathic system: case-control study’, by Ferreira B., Da Silva G.P., Gonçalves C.R., et al |
| Q39456770 | Semen analysis of Golden Retriever healthy dogs and those affected by muscular dystrophy. |
| Q46245053 | Skeletal Muscle Regenerative Potential of Human MuStem Cells following Transplantation into Injured Mice Muscle. |
| Q27304985 | Spatio-Temporal Differences in Dystrophin Dynamics at mRNA and Protein Levels Revealed by a Novel FlipTrap Line |
| Q50704888 | Stem cells from umbilical cord blood differentiate into myotubes and express dystrophin in vitro only after exposure to in vivo muscle environment. |
| Q36004069 | Stem cells isolated from human dental pulp and amniotic fluid improve skeletal muscle histopathology in mdx/SCID mice |
| Q53143745 | Stomatognathic function in Duchenne muscular dystrophy: a case-control study. |
| Q36841572 | Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy |
| Q55109195 | Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic mice. |
| Q38351283 | What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease? |
Search more.